secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001193125-23-211446
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD Q2 net loss narrows to $2.4M as royalty transition continues
---------------------------------------------------------------------------

- Net loss from continuing ops of $2.4M ($0.24 per share) vs $14.9M ($1.70) in Q2 2022.
- License and service revenue rose to $0.4M from $0.3M year-over-year, driven by Mayne License Agreement.
- Total operating expenses fell 80.4% to $2.9M reflecting wind-down of manufacturing and commercial ops.
- CEO says company is focused on cost reduction and cash conservation during ongoing business transformation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000119312523211446/0001193125-23-211446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000119312523211446/d513429d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-211446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer